Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Glutamate (Metabotropic) Group II Receptors
More Information »Metabotropic Glutamate (mGlu) group II receptors are members of the metabotropic class of glutamate receptors, which also includes mGlu group I and mGlu group III receptors. Group II receptors are divided into two subtypes, mGlu2 and mGlu3.
Glutamate (Metabotropic) Group II Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 0284 | (1S,3R)-ACPD |
| Group II/group I mGlu agonist | |
| 0186 | cis-ACPD |
| Selective group II agonist. Also potent NMDA agonist | |
| 0187 | (±)-trans-ACPD |
| Group II/group I mGlu agonist | |
| 1208 | (2R,4R)-APDC |
| Highly selective group II agonist | |
| 0329 | (S)-3-Carboxy-4-hydroxyphenylglycine |
| Selective group II mGlu agonist, also group I mGlu antagonist | |
| 0320 | (S)-4-Carboxy-3-hydroxyphenylglycine |
| Group II agonist/group I antagonist | |
| 0323 | (S)-4-Carboxyphenylglycine |
| Group I mGlu antagonist/weak group II agonist | |
| 0333 | L-CCG-l |
| Potent group II mGlu agonist | |
| 0975 | DCG IV |
| Very potent, selective group II mGlu agonist. Also NMDA agonist | |
| 3246 | LY 354740 |
| Potent and highly selective group II mGlu agonist | |
| 2453 | LY 379268 |
| Highly selective group II mGlu agonist | |
| 3272 | (±)-LY 395756 |
| mGlu group II agonist | |
| 0711 | MAP4 |
| Potent group II mGlu agonist. Also specific group III mGlu antagonist | |
| 3332 | NPEC-caged-LY 379268 |
| Caged group II mGlu receptor agonist | |
| 0391 | Spaglumic acid |
| Selective mGlu3 agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 1073 | (RS)-APICA |
| Selective group II antagonist | |
| 1009 | E4CPG |
| Group II/group I mGlu antagonist | |
| 0971 | EGLU |
| Highly selective group II mGlu antagonist | |
| 1209 | LY 341495 |
| Highly potent, selective group II antagonist | |
| 4062 | LY 341495 disodium salt |
| Disodium salt of LY 341495 (Cat. No. 1209) | |
| 3696 | (RS)-MCPG disodium salt |
| Non-selective mGlu antagonist | |
| 0336 | (RS)-MCPG |
| Non-selective mGlu antagonist | |
| 0337 | (S)-MCPG |
| Non-selective mGlu antagonist. Active isomer of Cat. No. 0336 | |
| 0854 | MSPG |
| Group II/group III mGlu antagonist | |
| 0855 | MTPG |
| Group II/group III mGlu antagonist. More selective for group II than group III | |
| 2913 | Ro 64-5229 |
| Selective, non-competitive mGlu2 antagonist | |
Modulators |
|
Cat.No. |
Product Name / Activity |
| 4048 | BINA |
| Selective positive allosteric modulator of mGlu2 | |
| 3949 | CBiPES hydrochloride |
| Positive allosteric modulator of mGlu2 | |
| 3283 | LY 487379 hydrochloride |
| Positive allosteric modulator selective for mGlu2 | |
| 4388 |
MNI 137
|
| Selective negative allosteric modulator of group II mGlu receptors | |
Activators |
|
Cat.No. |
Product Name / Activity |
| 4120 | Xanthurenic acid |
| Selectively activates group II mGlu receptors | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1827 | Group II mGlu Receptor Tocriset™ |
| Selection of 5 group II mGlu receptor ligands (Cat. Nos. 1208, 0975, 1209, 0971 and 0337) | |
| 1829 | Mixed mGlu Receptor Tocriset™ |
| Selection of 5 mixed mGlu receptor ligands (Cat. Nos. 0805, 0975, 0103, 0337 and 1209) | |
Related Categories
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
mGlu Receptors Review
Written by Francine Acher, an expert in the field. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
Tocris Events
Win a Kindle
June 15 - 18, 2013
San Francisco, CA
Booth Number: 1032